US equities
|
META
$624.70
▼-0.93%
TSLA
$403.93
▲+3.14%
MU
$923.18
▲+2.16%
NVDA
$217.67
▲+0.77%
AMD
$553.46
▲+4.17%
SPCX
$148.90
▲+1.36%
INTC
$93.50
▲+3.34%
SNDK
$1,292.23
▲+2.92%
META
$624.70
▼-0.93%
TSLA
$403.93
▲+3.14%
MU
$923.18
▲+2.16%
NVDA
$217.67
▲+0.77%
AMD
$553.46
▲+4.17%
SPCX
$148.90
▲+1.36%
INTC
$93.50
▲+3.34%
SNDK
$1,292.23
▲+2.92%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Latest News about Psychedelic Drug Development
Recent news which mentions Psychedelic Drug Development
$21.8M Revenue For NASDAQ-Listed Psychedelics Ancillary Company Societal CDMO's Q2 2023
August 16, 2023
Tickers
SCTL
Tags
Management
Psychedelic Drug Development
Penny Stocks
From
Benzinga